PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-46.40%
Negative revenue growth while AVGO stands at 17.91%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-61.49%
Negative gross profit growth while AVGO is at 26.24%. Joel Greenblatt would examine cost competitiveness or demand decline.
-408.27%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-408.27%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-339.14%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-346.43%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-342.86%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-1.13%
Share reduction while AVGO is at 10.80%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-3.67%
Reduced diluted shares while AVGO is at 11.93%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-146.15%
Negative OCF growth while AVGO is at 48.39%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
4.83%
FCF growth under 50% of AVGO's 31.58%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
214.06%
Positive 10Y revenue/share CAGR while AVGO is negative. John Neff might see a distinct advantage in product or market expansion over the competitor.
-8.16%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-21.22%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-413.82%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-1784.49%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-109.14%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-947.67%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-650.66%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-256.25%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
1510.75%
10Y equity/share CAGR above 1.5x AVGO's 20.90%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
105.29%
5Y equity/share CAGR above 1.5x AVGO's 20.90%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
70.43%
3Y equity/share CAGR above 1.5x AVGO's 20.90%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-47.61%
Firm’s AR is declining while AVGO shows 4.49%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
2.64%
Inventory shrinking or stable vs. AVGO's 5.88%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-8.17%
Negative asset growth while AVGO invests at 10.99%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.61%
We have a declining book value while AVGO shows 23.83%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-0.27%
Our R&D shrinks while AVGO invests at 10.17%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.33%
We cut SG&A while AVGO invests at 17.50%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.